Intervention

AZD6738

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 5 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5
Recruiting1
Common conditions9
Lead sponsors shown4
Advertisement

Clinical trials

5 shown
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerNCT03740893 · 2019-10-15
RECRUITING
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)NCT03787680 · 2019-10-31
ACTIVE_NOT_RECRUITING
Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]NCT03428607 · 2018-10-17
COMPLETED
The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialNCT03182634 · 2016-12-15
UNKNOWN
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerNCT02664935 · 2015-05-13
COMPLETED

Trial status mix

COMPLETED2
ACTIVE_NOT_RECRUITING1
RECRUITING1
UNKNOWN1

Phase mix

PHASE25

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.